SLC5A2 and type 2 diabetes mellitus: This is important, as in the recent years, different clinical trials have demonstrated that over the standard of care some glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2 inhibitors) reduce the risk of CV and renal outcomes in patients with T2D and high CVD risk and/or established CVD and/or chronic kidney disease [11–16].